Hidradenitis suppurativa is a common disease, but the evidence defining it has failed to keep pace with its clinical burden. Although it is a chronic inflammatory skin condition, it remains widely misunderstood and underdiagnosed.

For many patients, its impact extends far beyond the skin. Data consistently show that hidradenitis suppurativa disproportionately affects Black patients and is more prevalent among women, placing Black women among those carrying the greatest clinical toll. Large United States datasets demonstrate that Black patients have a significantly higher prevalence than White patients, with disease onset occurring at younger ages in many women of color. Despite this earlier onset, Black women frequently enter specialty care with more advanced disease, reflecting missed opportunities for early intervention.

While the disease is often framed as niche or overlooked in literature, its concentration within specific populations tells a very different story, one defined by unequal impact and prolonged suffering. This article examines the growing gap between disease burden and clinical evidence, particularly among patients with darker skin, who experience greater severity overall without proportional representation in clinical trials. Although research has expanded and treatment options have advanced, health inequities continue to shape unequal access to care, leaving discovery misaligned with the lived reality of the patients most affected.

Hidradenitis suppurativa does not affect all populations equally. Population-level analyses from United States cohorts and national databases show that the disease is more prevalent in Black populations than in White populations and is often diagnosed at younger ages. Women are disproportionately affected, and Black women sit at the intersection of multiple high-burden factors. Together, these data point to earlier onset, longer disease duration, and greater cumulative disease impact.

Clinically, Black patients are more likely to present with greater inflammatory involvement, higher reported pain severity, and more advanced disease by the time they reach specialty care. Studies consistently demonstrate higher rates of scarring, sinus tract formation, and healthcare utilization, markers of prolonged and inadequately controlled disease. Pain remains one of the most consistent and life-altering features of hidradenitis suppurativa, yet it is routinely minimized in both research endpoints and clinical conversations, despite being the symptom patients most often describe as limiting their daily lives. This disconnect between lived experience and measured outcomes directly shapes how the disease is studied, treated, and assessed for severity.

These patterns are not biological inevitabilities. They reflect systemic delays and structural barriers within healthcare. Diagnostic delays not only allow the disease to progress, but they also determine when patients enter care, whether they qualify for clinical trials, and how their outcomes are ultimately interpreted. Patients who enter studies later in the disease course may respond differently from those diagnosed earlier, yet time to diagnosis is rarely examined as a meaningful modifier of trial outcomes. Differences in presentation, therefore, reflect delayed recognition and access rather than inherent differences in disease biology.

Over the past decade, research has shifted toward biologics and targeted therapies, with large phase three trials forming the backbone of evidence guiding treatment decisions. This progress is promising, but it also exposes important limitations in how evidence is generated. Race is more frequently reported at baseline in modern trials, and Black patients are included in many contemporary study programs, though enrollment remains uneven. Enrollment, however, remains disproportionate to real-world prevalence. As long as both are collected (Race and Sex) they can make intersectional or multivariate analyses but it’s also possible that they may not run these analyses and report them.

Primary endpoints continue to focus on lesion counts and inflammatory response. While necessary for regulatory approval, these measures capture only part of the disease experience. Pain severity, quality of life impact, functional limitation, and stigma are often collected but rarely analyzed in ways that reflect racial or sex-based differences. This emphasis is not incidental. Lesion counts and inflammatory markers are easier to standardize, quantify, and defend in regulatory settings, even when they fail to reflect the outcomes patients find most meaningful. As a result, pain, functional limitation, and long-term skin changes are frequently treated as secondary considerations rather than central indicators of treatment success. The evidence base, therefore, fails to fully reflect the scope of disease experienced by the patients most affected.

Some sponsors have taken steps toward improved diversity reporting. Race is now more commonly included in baseline demographics, and disparities in disease impact are occasionally acknowledged in trial introductions or discussion sections. Still, these efforts stop short of meaningful change. Trial eligibility criteria may unintentionally exclude patients with more advanced or complex disease, precisely those who experience the greatest cumulative effects. Requirements related to prior treatment exposure, disease duration, or comorbidities shape who is eligible to enroll and, ultimately, whose disease defines the evidence base.

Until research is designed around the patients carrying the greatest burden, those with advanced disease, persistent pain, and long-term sequelae, the gap between lived reality and clinical evidence will continue to widen. When discovery is shaped around the most convenient trial candidate rather than the most affected patient, inequity becomes embedded not only in research but in care itself.

References

Garg, A., Kirby, J. S., Lavian, J., Lin, G., & Strunk, A. (2017). Prevalence estimates for hidradenitis suppurativa among children and adults in the United States. JAMA Dermatology, 153(8), 760–764.

https://jamanetwork.com/journals/jamadermatology/fullarticle/2626146

Sachdeva, M., Ghias, M. H., Ramachandran, R., & Alavi, A. (2021). Global prevalence of hidradenitis suppurativa: A systematic review. Dermatology, 237(3), 415–425.

https://pubmed.ncbi.nlm.nih.gov/33174482/

Young, P. M., et al. (2024). Hidradenitis suppurativa severity in patients with skin of color. Journal of the American Academy of Dermatology.

https://www.sciencedirect.com/science/article/abs/pii/S0190962224031219

Edigin, E., et al. (2021). Racial disparities in hidradenitis suppurativa–related hospitalizations in the United States. JAMA Dermatology, 157(6), 705–712.

https://jamanetwork.com/journals/jamadermatology/fullarticle/2782888

Serrano, L., et al. (2023). Diagnostic delay and access to specialty care in hidradenitis suppurativa. Journal of the American Academy of Dermatology.

https://pubmed.ncbi.nlm.nih.gov/36511276/

Negbenebor, N., et al. (2024). Structural barriers and delayed diagnosis among Black patients with hidradenitis suppurativa. Clinical, Cosmetic and Investigational Dermatology.

https://pmc.ncbi.nlm.nih.gov/articles/PMC12454235/

Choi, J., et al. (2024). Race and ethnicity reporting in hidradenitis suppurativa clinical trials. JAAD International.

https://pubmed.ncbi.nlm.nih.gov/41329138/

Thorlacius, L., et al. (2018). Outcome measures and patient-reported burden in hidradenitis suppurativa trials. Journal of the European Academy of Dermatology and Venereology, 32(1), 95–102.

McMillan, K., et al. (2020). Pain and quality-of-life burden in hidradenitis suppurativa. British Journal of Dermatology, 183(2), 312–319.

Reddy, S., et al. (2021). Limitations in demographic reporting in dermatologic clinical trials. JAAD International.

Alavi, A., et al. (2022). Gaps in demographic granularity in hidradenitis suppurativa research. British Journal of Dermatology.

Dermatology Advisor. (2023). Clinical characteristics of hidradenitis suppurativa vary by race, ethnicity, and sex.

Clinical Characteristics Vary by Race/Ethnicity, Sex in Hidradenitis Suppurativa

Plastic and Reconstructive Surgery – Global Open. (2025). Racial disparities in hidradenitis suppurativa.

https://journals.lww.com/prsgo/fulltext/2025/06000/racial_disparities_in_hidradenitis_suppurativa.32.aspx

All of Us Research Program. (2024). Prevalence of hidradenitis suppurativa by age and race in the United States.

https://www.researchgate.net/publication/389254767_Hidradenitis_Suppurativa_Prevalence_by_Age_and_Race_in_the_United_States